Psychemedics, a global leader in the drug screening industry, has “proudly” announced the launch of a “revolutionary” drug screening panel that removes marijuana and emphasizes fentanyl.
According to a press release, this “groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl.”
Complemented by the detection of cocaine, opioids, PCP, and amphetamines, the advanced panel is “a leap forward” in drug screening technology.
“Few challenges in the workplace have undergone as dramatic a transformation as the shifting dynamics between marijuana and fentanyl,” remarked Brian Hullinger, President and CEO at Psychemedics. “Recognizing this shift, Psychemedics has developed the Advanced 5-Panel to bridge the gap.”
The Advanced 5-Panel Drug Screen offers clients a cost-effective choice to adapt their testing protocols in sync with evolving priorities and employment policies. It “ensures that resources and dollars are invested in identifying the threats that matter most to organizations today.”
The impact of this offering is not merely theoretical; it is supported by a recent independent study encompassing nearly 1 million drug tests. The findings demonstrate that hair testing outperforms traditional methods in detecting the most abused substances, such as opioids, cocaine, and amphetamines:
- 25 times more effective at detecting opioids.
- 23 times more accurate in identifying cocaine use.
- 13 times more adept at pinpointing amphetamine use.
The Advanced 5-Panel Drug Screen “is crafted to focus exclusively on these critical threats, ensuring the highest level of security for organizations.”
